Quick Answer
INTENSITY THERAPEUTICS, INC. reported Operating Income Loss of -$11.97 million for the year ending 2025.
- INTENSITY THERAPEUTICS, INC. showed an increase of +27.8% in Operating Income Loss from 2024 to 2025.
- This data is from INTENSITY THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on March 27, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2022: -$1.93 million | Q3 2022: -$1.77 million | Q1 2023: -$1.25 million | Q2 2023: -$1.22 million | Q3 2023: -$2.49 million | Q1 2024: -$4.74 million | Q2 2024: -$5.07 million | Q3 2024: -$3.57 million | Q1 2025: -$3.39 million | Q2 2025: -$2.71 million | Q3 2025: -$2.73 million.
- Over the full 4 years of available data (2022 to 2025), INTENSITY THERAPEUTICS, INC.'s Operating Income Loss has declined by 58.6%.
- Historical annual values: Fiscal year 2025: -$11.97 million | Fiscal year 2024: -$16.59 million | Fiscal year 2023: -$8.32 million | Fiscal year 2022: -$7.55 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: